Lenalidomide-induced Interstitial Pneumonitis

Shafi, Azhar; Rehman, Jalil Ur; Nawaz, Azhar; AlJohani, Naif I.

doi:10.29271/jcpsp.2020.10.1117

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term IMiDs used continuously, like maintenance treatment for MM, may raise the frequency of uncontrolled immunostimulatory diseases by inducing a chronic inflammatory response, resulting in certain autoimmune diseases covering vasculitis, rashes, optic neuritis, interstitial pneumonitis, Graves’ disease, and polymyositis ( Montefusco et al, 2014 ; Brissot et al, 2015 ; Shao et al, 2017 ; Phan et al, 2020 ; Shafi et al, 2020 ; Cippitelli et al, 2021 ).…”

Section: Clinical Applicationsmentioning

confidence: 99%

Ikaros Proteins in Tumor: Current Perspectives and New Developments

Xia

Yuan

Han

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Ikaros is a zinc finger transcription factor (TF) of the Krüppel family member, which significantly regulates normal lymphopoiesis and tumorigenesis. Ikaros can directly initiate or suppress tumor suppressors or oncogenes, consequently regulating the survival and proliferation of cancer cells. Over recent decades, a series of studies have been devoted to exploring and clarifying the relationship between Ikaros and associated tumors. Therapeutic strategies targeting Ikaros have shown promising therapeutic effects in both pre-clinical and clinical trials. Nevertheless, the increasingly prominent problem of drug resistance targeted to Ikaros and its analog is gradually appearing in our field of vision. This article reviews the role of Ikaros in tumorigenesis, the mechanism of drug resistance, the progress of targeting Ikaros in both pre-clinical and clinical trials, and the potential use of associated therapy in cancer therapy.

show abstract